This issue brief summarizes the findings of a recent AMA, Colorado Medical Society, Colorado Pain Society and Manatt Health report submitted to the Colorado Division of Insurance in support of multidisciplinary, multimodal pain care.
Putting Evidence Into Practice: Buprenorphine Maintenance vs. Methadone Maintenance or Placebo for Opioid Use Disorder. Elizabeth Salisbury-Afshar, MD, MPH, Heartland Health Outreach, Chicago, Illinois. Am Fam Physician. 2015 Feb 1;91(3):165-166.
Use of this form by state regulators--and health insurers--can help ensure meaningful state oversight and compliance with the federal Mental Health Parity and Addiction Equity Act. This guides health insurers through the necessary analysis to demonstrate compliance with the law, which can then be made available to a state department of insurance to streamline regulatory review.
Fulfill your state-mandated CME credits while enhancing your knowledge of opioid and non-opioid pain management, safe opioid prescribing and substance use treatment. Learn now. CME 44.25 Total Credits
The AMA believes it is essential for formularies to also include a broad range of evidence-based pain care options. This resource is meant to provide an overview for policymakers of the types of treatments practicing physicians use to treat pain but may be subject to formulary exclusion or administrative barriers such as prior authorization or step therapy, or subject to cost-prohibitive co-pays, cost sharing and adverse formulary tiering.
Given the complex needs of pregnant and postpartum women and their children, and the number of systems they encounter during critically important periods in their lives, ASAM provides policy recommendations on substance use, misuse, and SUDs during and following pregnancy.
JAMA Psychiatry Traci C. Green, PhD, MSc; Jennifer Clarke, MD; Lauren Brinkley-Rubinstein, PhD; Brandon D. L. Marshall, PhD; Nicole Alexander-Scott, MD, MPH; Rebecca Boss, MA; Josiah D. Rich, MD, MPH
The AMA Opioid Task Force urges physicians and other health care professions to continue taking action to help reverse the nation’s opioid epidemic—and the Task Force also calls on policymakers to take specific steps to remove barriers to evidence-based care for patients with pain and those with a substance use disorder.Learn More